Clinical Trials Logo

Mitochondrial Myopathies clinical trials

View clinical trials related to Mitochondrial Myopathies.

Filter by:

NCT ID: NCT01301235 Completed - Clinical trials for Mitochondrial Disease

Defining 31Phosphorous Magnetic Resonance Spectroscopy Characteristics in Patients With Mitochondrial Myopathy

Start date: February 2011
Phase: N/A
Study type: Observational

This is a developmental protocol to determine the MRI based 31P-MRS changes seen in subjects with mitochondrial myopathy using our dynamic exercise protocol and to identify the ideal variable(s) to represent mitochondrial function.

NCT ID: NCT00840112 Terminated - Clinical trials for Peripheral Neuropathy

Vitamin E Treatment for Long-Chain 3-Hydroxyacyl Coenzyme A (CoA) Dehydrogenase (LCHAD) Associated Neuropathy

Start date: July 2010
Phase: N/A
Study type: Interventional

Purpose: People with a genetic defect in the ability to burn fat can also develop a problem with the nerves in their feet. The nerve problem, or neuropathy, can limit their ability to walk. Part of the treatment of their genetic defect in the ability to burn fat is to eat a very low fat diet. Vitamin E is found only in fatty foods like oils and nuts. People with a genetic defect in the ability to burn fat may have low vitamin E because of their low fat diet. The purpose of this study is to test whether vitamin E supplements can improve the nerve function in the feet of people with a genetic defect in the ability to burn fat. Procedures: Blood samples will be drawn at the beginning of the study, after 2 months and after 6 months of vitamin E supplements. The blood will be analyzed for plasma vitamin E concentrations. Around the time of each blood draw subjects will record all the food and beverages he or she consumes for three days. The subject will send the record to the investigator. Subjects will have a physical exam by a doctor specializing in nerves, a neurologist before and after taking vitamin E. They will have nerve function measured with a test called a nerve conduction velocity or NCV. Subjects will be given 800 international units (IU) of vitamin E per day for 6 months.

NCT ID: NCT00654004 Completed - Clinical trials for Trifunctional Protein Deficiency

Fatty Acid Oxidation Disorders & Body Weight Regulation Grant

Start date: April 2006
Phase: N/A
Study type: Observational

Several hormones involved in body weight regulation increase the subject's ability to burn fat for energy. The purpose of this study is to investigate how burning fat for energy may affect those hormones and body weight in children. The study will also determine if eating a diet higher in protein alters the amount of fat you burn and how these hormones control body weight.

NCT ID: NCT00457314 Recruiting - Clinical trials for Mitochondrial Myopathy

The Effects of Exercise Versus Inactivity on People With Mitochondrial Muscle Disease

Start date: June 2007
Phase: Phase 2
Study type: Interventional

Mitochondrial myopathies include various inherited diseases that are caused by damage to the mitochondria, energy-producing structures that fuel the body's processes. The main symptoms are muscle weakness, reduced muscle mass, and difficulty with exercising. The purpose of this study is to determine the effects of exercise training versus inactivity on mitochondrial function in muscle and muscle performance in people with mitochondrial myopathies.

NCT ID: NCT00004770 Completed - Clinical trials for Mitochondrial Myopathy

Pilot Compassionate Use Study of Thioctic Acid Treatment in Mitochondrial Myopathy

Start date: October 1995
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Assess the efficacy of thioctic acid in treating a single patient with mitochondrial myopathy.

NCT ID: NCT00004353 Completed - Lactic Acidosis Clinical Trials

Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia

Start date: December 1978
Phase: N/A
Study type: Observational

OBJECTIVES: I. Study the metabolism of pyruvate and related problems in patients with lactic acidemia. II. Define the nature of the metabolic defect.